Effects of (-)-epigallocatechin-3-gallate on egfr- or fusion gene-driven lung cancer cells

Yoshihiro Honda, Nagio Takigawa, Eiki Ichihara, Takashi Ninomiya, Toshio Kubo, Nobuaki Ochi, Masayuki Yasugi, Toshi Murakami, Hiromichi Yamane, Mitsune Tanimoto, Katsuyuki Kiura

Research output: Contribution to journalArticle

Abstract

(-)-Epigallocatechin-3-gallate (EGCG) has been shown to bind to several receptors including epidermal growth factor receptor (EGFR). EGFR tyrosine kinase inhibitors and anaplastic lymphoma kinase (ALK) inhibitors are effective for non-small cell lung cancers harboring activating EGFR mutations and ALK or c-ros oncogene 1 (ROS1) fusion genes, respectively. We investigated the effects of EGCG on EGFR- or fusion gene-driven lung cancer cells such as PC-9, RPC-9, H1975, H2228 and HCC78. The five cell lines had similar sensitivity to EGCG. Phosphorylated (p)EGFR, pAkt and pErk in PC-9, RPC-9 and H1975 cells were suppressed by EGCG (50 or 100 μM). EGCG also inhibited pALK in H2228, pROS1 in HCC78, and pErk and pAkt in both cell lines. All the xenograft tumors established using the 5 cell lines in EGCG-treated groups were significantly smaller than the tumors in the vehicle-treated groups. The numbers of tumor blood vessels of xenograft tissues in EGCG-treated mice were significantly lower than those in vehicle-treated mice. In conclusion, EGCG may be effective for EGFR-driven lung tumors irrespective of the presence of T790M, and for ALK or ROS1 fusion gene-driven lung tumors.

Original languageEnglish
Pages (from-to)505-512
Number of pages8
JournalActa Medica Okayama
Volume71
Issue number6
Publication statusPublished - Jan 1 2017

Fingerprint

Gene Fusion
Lung Neoplasms
Fusion reactions
Genes
Cells
Epidermal Growth Factor Receptor
Tumors
Heterografts
Cell Line
Neoplasms
Vascular Tissue Neoplasms
erbB-1 Genes
Lung
epigallocatechin gallate
Blood vessels
Oncogenes
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Tissue
Mutation

Keywords

  • ALK
  • EGFR
  • Epigallocatechin-3-gallate
  • lung cancer
  • ROS1

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Effects of (-)-epigallocatechin-3-gallate on egfr- or fusion gene-driven lung cancer cells. / Honda, Yoshihiro; Takigawa, Nagio; Ichihara, Eiki; Ninomiya, Takashi; Kubo, Toshio; Ochi, Nobuaki; Yasugi, Masayuki; Murakami, Toshi; Yamane, Hiromichi; Tanimoto, Mitsune; Kiura, Katsuyuki.

In: Acta Medica Okayama, Vol. 71, No. 6, 01.01.2017, p. 505-512.

Research output: Contribution to journalArticle

Honda, Y, Takigawa, N, Ichihara, E, Ninomiya, T, Kubo, T, Ochi, N, Yasugi, M, Murakami, T, Yamane, H, Tanimoto, M & Kiura, K 2017, 'Effects of (-)-epigallocatechin-3-gallate on egfr- or fusion gene-driven lung cancer cells', Acta Medica Okayama, vol. 71, no. 6, pp. 505-512.
Honda, Yoshihiro ; Takigawa, Nagio ; Ichihara, Eiki ; Ninomiya, Takashi ; Kubo, Toshio ; Ochi, Nobuaki ; Yasugi, Masayuki ; Murakami, Toshi ; Yamane, Hiromichi ; Tanimoto, Mitsune ; Kiura, Katsuyuki. / Effects of (-)-epigallocatechin-3-gallate on egfr- or fusion gene-driven lung cancer cells. In: Acta Medica Okayama. 2017 ; Vol. 71, No. 6. pp. 505-512.
@article{7d25236e15c54bb0946b3c30e5b21599,
title = "Effects of (-)-epigallocatechin-3-gallate on egfr- or fusion gene-driven lung cancer cells",
abstract = "(-)-Epigallocatechin-3-gallate (EGCG) has been shown to bind to several receptors including epidermal growth factor receptor (EGFR). EGFR tyrosine kinase inhibitors and anaplastic lymphoma kinase (ALK) inhibitors are effective for non-small cell lung cancers harboring activating EGFR mutations and ALK or c-ros oncogene 1 (ROS1) fusion genes, respectively. We investigated the effects of EGCG on EGFR- or fusion gene-driven lung cancer cells such as PC-9, RPC-9, H1975, H2228 and HCC78. The five cell lines had similar sensitivity to EGCG. Phosphorylated (p)EGFR, pAkt and pErk in PC-9, RPC-9 and H1975 cells were suppressed by EGCG (50 or 100 μM). EGCG also inhibited pALK in H2228, pROS1 in HCC78, and pErk and pAkt in both cell lines. All the xenograft tumors established using the 5 cell lines in EGCG-treated groups were significantly smaller than the tumors in the vehicle-treated groups. The numbers of tumor blood vessels of xenograft tissues in EGCG-treated mice were significantly lower than those in vehicle-treated mice. In conclusion, EGCG may be effective for EGFR-driven lung tumors irrespective of the presence of T790M, and for ALK or ROS1 fusion gene-driven lung tumors.",
keywords = "ALK, EGFR, Epigallocatechin-3-gallate, lung cancer, ROS1",
author = "Yoshihiro Honda and Nagio Takigawa and Eiki Ichihara and Takashi Ninomiya and Toshio Kubo and Nobuaki Ochi and Masayuki Yasugi and Toshi Murakami and Hiromichi Yamane and Mitsune Tanimoto and Katsuyuki Kiura",
year = "2017",
month = "1",
day = "1",
language = "English",
volume = "71",
pages = "505--512",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "6",

}

TY - JOUR

T1 - Effects of (-)-epigallocatechin-3-gallate on egfr- or fusion gene-driven lung cancer cells

AU - Honda, Yoshihiro

AU - Takigawa, Nagio

AU - Ichihara, Eiki

AU - Ninomiya, Takashi

AU - Kubo, Toshio

AU - Ochi, Nobuaki

AU - Yasugi, Masayuki

AU - Murakami, Toshi

AU - Yamane, Hiromichi

AU - Tanimoto, Mitsune

AU - Kiura, Katsuyuki

PY - 2017/1/1

Y1 - 2017/1/1

N2 - (-)-Epigallocatechin-3-gallate (EGCG) has been shown to bind to several receptors including epidermal growth factor receptor (EGFR). EGFR tyrosine kinase inhibitors and anaplastic lymphoma kinase (ALK) inhibitors are effective for non-small cell lung cancers harboring activating EGFR mutations and ALK or c-ros oncogene 1 (ROS1) fusion genes, respectively. We investigated the effects of EGCG on EGFR- or fusion gene-driven lung cancer cells such as PC-9, RPC-9, H1975, H2228 and HCC78. The five cell lines had similar sensitivity to EGCG. Phosphorylated (p)EGFR, pAkt and pErk in PC-9, RPC-9 and H1975 cells were suppressed by EGCG (50 or 100 μM). EGCG also inhibited pALK in H2228, pROS1 in HCC78, and pErk and pAkt in both cell lines. All the xenograft tumors established using the 5 cell lines in EGCG-treated groups were significantly smaller than the tumors in the vehicle-treated groups. The numbers of tumor blood vessels of xenograft tissues in EGCG-treated mice were significantly lower than those in vehicle-treated mice. In conclusion, EGCG may be effective for EGFR-driven lung tumors irrespective of the presence of T790M, and for ALK or ROS1 fusion gene-driven lung tumors.

AB - (-)-Epigallocatechin-3-gallate (EGCG) has been shown to bind to several receptors including epidermal growth factor receptor (EGFR). EGFR tyrosine kinase inhibitors and anaplastic lymphoma kinase (ALK) inhibitors are effective for non-small cell lung cancers harboring activating EGFR mutations and ALK or c-ros oncogene 1 (ROS1) fusion genes, respectively. We investigated the effects of EGCG on EGFR- or fusion gene-driven lung cancer cells such as PC-9, RPC-9, H1975, H2228 and HCC78. The five cell lines had similar sensitivity to EGCG. Phosphorylated (p)EGFR, pAkt and pErk in PC-9, RPC-9 and H1975 cells were suppressed by EGCG (50 or 100 μM). EGCG also inhibited pALK in H2228, pROS1 in HCC78, and pErk and pAkt in both cell lines. All the xenograft tumors established using the 5 cell lines in EGCG-treated groups were significantly smaller than the tumors in the vehicle-treated groups. The numbers of tumor blood vessels of xenograft tissues in EGCG-treated mice were significantly lower than those in vehicle-treated mice. In conclusion, EGCG may be effective for EGFR-driven lung tumors irrespective of the presence of T790M, and for ALK or ROS1 fusion gene-driven lung tumors.

KW - ALK

KW - EGFR

KW - Epigallocatechin-3-gallate

KW - lung cancer

KW - ROS1

UR - http://www.scopus.com/inward/record.url?scp=85038815673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038815673&partnerID=8YFLogxK

M3 - Article

VL - 71

SP - 505

EP - 512

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 6

ER -